Analysts consider AtaiBeckley’s MDMA candidate a “high-risk, high-reward” bet after the drug demonstrated reductions in ...

EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability ...

Investing.com -- Shares of drug developer AtaiBeckley (ATAI.O) rose 2% to $4.42 in premarket trading on Thursday. The company said its experimental R-MDMA pill, designed to treat severe fear of social ...

AtaiBeckley Inc. recently announced it will host a Virtual Investor Day on March 6, 2026, and appointed veteran life sciences executive Michael Faerm as incoming Chief Financial Officer, with former ...

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...

- Srinivas RaoM.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer, ...

​AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Will Skyrocket. Wall Street is bullish on AtaiBeckley Inc. (NASDAQ:ATAI) with analysts’ 12-month median price target reflecting ...

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of ...

Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...

ATAI, has completed its merger with Beckley Psytech, bringing lead compound BPL-003 fully in house. BPL-003 has received FDA Breakthrough Therapy designation for treatment resistant depression. Recent ...

atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...

atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...